- $62.5M Series B led by Camber Partners, with existing investors participating.
- Respond.io is profitable with $35M ARR, 169% year-over-year growth, and a 30% profit margin.
- New capital will fund expansion into and mergers and acquisitions within North America and Europe.
KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 16 June 2026 - Respond.io, a Malaysia-based customer conversation management platform, today announced a $62.5 million Series B round led by Camber Partners, with participation from Endeavor Catalyst and existing investors.
What respond.io does
Respond.io enables mid-market B2C businesses to grow revenue from high volumes of customer chats and calls. It unifies WhatsApp, Instagram, TikTok, Messenger, LINE, Telegram, WeChat, voice calls, email, web chat and 16 more integrations into a single platform with AI agents, automation, and CRMs. This turns fragmented customer conversations into a measurable revenue engine, purpose-built for real-world scale and complexity.
The company serves industries where customers initiate conversations before buying, booking, or committing, including education, healthcare, automotive, retail and travel. The platform powers 2 billion messages per quarter for more than 10,000 businesses in over 180 countries, including Toyota, British Airways, Radisson, Hertz, and Decathlon.
Respond.io generates $35M in annual recurring revenue, growing 169% year-over-year, at a 30% profit margin. It is ISO 27001 certified, GDPR compliant, and an official Meta Business and TikTok Marketing Partner.
Why Camber Partners
The funding was led by Camber Partners, a New York City-based growth equity firm that invests in only a handful of capital-efficient software businesses per year, with a pre-fund portfolio that includes Dropbox, PandaDoc, and Pipedrive. Camber brings deep operational engagement to their partnerships, including support in go-to-market, data science, and talent. As a US-based firm with European market experience, the relationship maps directly to respond.io's geographic expansion plans.
"When we started talking to Camber Partners, that conversation felt different," said Gerardo Salandra, CEO and co-founder of respond.io. "We built respond.io over nine years across markets most competitors never entered and did it profitably. Camber Partners and other investors backed us because they understand what that means: real product-market fit, with great unit economics, and a business that raises to accelerate, not to survive."
"Respond.io spent nine years building the infrastructure for high consideration, AI-native customer conversations - and they did it profitably in diverse markets. They have an exceptional team that has leveraged AI to accelerate rapidly. We believe respond.io is positioned to lead this category at a global scale," said Scott Irwin, founder and partner, Camber Partners.
From omnichannel inbox to native AI infrastructure
Respond.io launched in 2017 to solve a straightforward problem: customers were moving to messaging apps, but businesses struggled to respond from separate channel inboxes. The founding team built a platform that consolidated fragmented conversations into a single platform with automation and routing.
As frontier LLMs matured, the team realized this foundation was exactly what autonomous agents needed to operate on to enable rapid revenue acceleration for the high-consideration businesses they serve. Respond.io had spent years assembling the infrastructure — every major messaging channel, voice, email, CRM integrations, compliance controls — and accumulating the kind of operational depth that comes only from years of running high-volume conversations. This enabled it to roll out native AI technologies that meaningfully address real business needs.
This advantage is structural and compounds over time. Processing more conversations than any comparable platform creates a data flywheel — aggregate intelligence about how businesses actually deploy AI in high-volume messaging, the patterns that work, the edge cases that don't — that continuously shapes how respond.io's AI features are built and improved. Newer or lighter platforms building on the same frontier models cannot buy these operational signals or guarantee the same 99.999% uptime at the volumes AI brings. Today, Respond.io's AI Agents engage thousands of leads daily, qualify them and close B2C sales autonomously, handing off to human operators with full context for edge cases.
The speed of respond.io's innovation attracted some of the largest partners in the ecosystem. Meta and TikTok chose respond.io for early rollouts of WhatsApp Business Calling API, TikTok Business Messaging, and TikTok Messaging Ads — making it one of the few platforms offering end-to-end integrations for both messaging and calling.
"Most businesses still treat customer conversations as a cost to manage. The ones winning right now treat them as the revenue channel they actually are, and they're automating everything that doesn't require a human so the humans can focus where they add the most value," Salandra said. "We see it in our customers every day — we have case studies showing AI Agents are handling 600% more leads with conversation rates as high as 84%."
Entering North America and Europe
Respond.io built category leadership across APAC, LATAM and EMEA from its base in Malaysia — markets where mobile messaging is the primary commercial channel — and reached profitability doing so. The capital from this new round will accelerate the company's expansion in North America and Europe, where social commerce on TikTok, Instagram, and WhatsApp is growing, and mid-market B2C businesses are increasingly running the same types of revenue-critical conversations that respond.io has powered for years.
"The customer conversation management space is at an inflection point," Salandra said. "North America and Western Europe are moving toward leveraging conversations as a competitive advantage to generate revenue, using similar workflows we've already built and tested in markets where this shift happened first. We know how to serve these businesses, and with this funding, we now have the resources to reach them faster."
Reid Hoffman, co-founder of LinkedIn and Chairman of Endeavor Catalyst commented: "We are thrilled to be investing in respond.io in this new round. Respond.io is exactly the kind of company we are proud to support — founders building profitable infrastructure in emerging markets and scaling them into the world's largest economies. So proud to have them in the Endeavor Catalyst family!"
Hashtag: #respondio #seriesb
https://respond.io
https://www.linkedin.com/company/respondio
https://x.com/respond_io
https://www.facebook.com/getrespondio
https://www.instagram.com/respond.io/
https://youtube.com/c/@respondio
The issuer is solely responsible for the content of this announcement.
About Respond.io
Respond.io is a customer conversation management platform that unifies messaging, calls, email, and CRM to help mid-market B2C businesses drive revenue from customer conversations. The platform powers 2 billion messages per quarter for 10,000+ businesses in over 180 countries and territories with 99.999% platform uptime. Respond.io is ISO 27001 certified, GDPR compliant, and an official Meta Business and TikTok Marketing partner. Founded in 2017 and headquartered in Kuala Lumpur, Malaysia, it raised US$7 million in Series A funding in 2022. For more information, visit https://respond.io.
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
CUHK’s Dean of Medicine Professor Philip Chiu Wai-yan appointed Dean of Medicine at CUHK-Shenzhen Leveraging the two CUHK medical centres in Hong Kong and Shenzhen to foster an international hub for medical talent and innovation in the region
HONG KONG SAR – Media OutReach Newswire – 30 October 2026 – The Chinese University of Hong Kong (CUHK) has been deeply engaged in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) for more than two decades. Through 45 years of dedicated development, the CUHK Faculty of Medicine (CU Medicine) has become a world-leading medical school. Recognising the immense growth potential and future healthcare needs of the GBA, CUHK will fulfill its distinctive "One Brand, Two Campuses" vision, integrate the complementary strengths of its campuses in Hong Kong and Shenzhen, and advance cross-campus collaboration by appointing Professor Philip Chiu Wai-yan, Dean of Medicine at CUHK, to concurrently serve as Dean of Medicine at The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen). Professor Chiu will also be appointed as Associate Vice President (Medical Affairs) of CUHK-Shenzhen, with a term aligned with his current tenure as Dean of Medicine at CUHK. The appointments will take effect on 1 November 2026. He will oversee the strategic development, academic planning and collaboration initiatives of both medical schools, while leading global recruitment efforts to attract top medical talent.
CUHK's Dean of Medicine Professor Philip Chiu appointed Dean of Medicine at CUHK-Shenzhen
This appointment marks a significant strategic move under the "One Brand, Two Campuses" vision. It will further strengthen the capabilities and advantages of both campuses in medical education, translational research and clinical excellence. By leveraging the crucial clinical and research platforms provided by the two CUHK medical centres in Hong Kong and Shenzhen, CUHK aims to advance medical innovation and the internationalisation of medical education, cultivate top global healthcare professionals, elevate regional healthcare standards and serve the broader GBA. The initiative is also aligned with the National 15th Five-Year Plan and the First Five-Year Plan of the Hong Kong Special Administrative Region.
Under the governance and management framework of CUHK, Professor Chiu will be accountable to both CUHK and CUHK-Shenzhen campuses. He also serves as a member of the Board of Directors of CUHK Medical Centre. Under his leadership, the two medical schools will further deepen collaboration under their respective governance principles and frameworks, making full use of the two teaching hospitals, namely CUHK Medical Centre and CUHK-Shenzhen Medical Centre, to enhance clinical research capacity, accelerate the translation of cutting-edge medical technologies, strengthen medical talent development and contribute to improving medical education and clinical research across the GBA.
Deep roots in the GBA and a strong foundation of Hong Kong-Shenzhen collaboration
CUHK has maintained a presence in the GBA for more than 20 years. As early as 2006, it co-established the Shenzhen Institute of Advanced Technology, gradually building a multi-layered network of academic, research and healthcare partnerships. Founded in 2014, CUHK-Shenzhen inherits CUHK's educational philosophy to "combine tradition with modernity, and to bring together China and the West". It serves as CUHK's campus in Shenzhen and extends CUHK's educational brand into the GBA.
To support the national GBA development strategy, CUHK and CUHK-Shenzhen have prioritised medical collaboration since 2018 through the establishment of the School of Medicine at CUHK-Shenzhen and the development of a comprehensive teaching hospital. The two campuses will maintain close strategic coordination in management and development. while continuing collaboration in teaching, research and talent cultivation.
Drawing on the experience of CU Medicine, these initiatives aim to nurture healthcare professionals with international perspectives, professional excellence and humanistic values to meet the healthcare and public health needs of the GBA, as well as the nation as a whole.
Strategic appointment to realise the synergy of "One Brand, Two Campuses"
Professor John Chai Yat-chiu, Chairman of the CUHK Council, highly commended the appointment: "As an important manifestation of the 'One Brand, Two Campuses' strategy, this dual-appointment brings together the medical research strengths and advantages of Hong Kong and Shenzhen. It will expand the clinical research network and educational platforms of both medical schools, enhance the Greater Bay Area's competitiveness in international medical innovation and cultivate globally-minded healthcare talent. It will also help attract leading medical professionals from around the world to the region, creating mutual benefits for the development of academic medicine and healthcare systems across the Greater Bay Area, while supporting the National 15th Five-Year Plan and the First Five-Year Plan of the Hong Kong Special Administrative Region."
Professor Dennis Lo Yuk-ming, CUHK's Vice-Chancellor and President and Chairman of the Governing Board of CUHK-Shenzhen, said: "Rooted in Hong Kong, contributing to the nation and connected to the world, CUHK is taking an important step in focusing on the long-term development of the Greater Bay Area and advancing its strategic footprint in healthcare innovation across the region through this appointment. Professor Philip Chiu's outstanding academic achievements and international vision make him exceptionally well suited for this role. Under his leadership, the two medical schools will deepen collaboration while adhering to the established governance principles, injecting new momentum into the development of medical technology and higher education in Hong Kong, Shenzhen and across the nation."
Professor Xu Yangsheng, President of CUHK-Shenzhen, warmly welcomed Professor Chiu's appointment: "Since its establishment, the School of Medicine at CUHK-Shenzhen has been committed to developing a world-class system for medical education and research, raising healthcare standards across the Greater Bay Area and the broader nation. Professor Chiu is internationally renowned and possesses extensive leadership experience. We look forward to his leadership in accelerating the growth of the medical school, attracting outstanding global talent and serving the healthcare and public health needs of the Greater Bay Area, as well as the nation as a whole."
Professor Chiu expressed his gratitude and shared his vision for the future: "Strengthening collaboration between Hong Kong and Shenzhen in medical education and research is key to driving high-quality healthcare development in the Greater Bay Area and across the wider nation. I will devote my full efforts to fostering deep-level synergy between the two medical schools across education, research and clinical innovation to achieve a powerful '1 + 1 > 2' effect. This appointment will enable CU Medicine to further expand its clinical data and translational research platforms, reinforcing Hong Kong's position as an international hub for medical innovation. At the same time, it will accelerate the internationalisation of the School of Medicine at CUHK-Shenzhen, attract top-tier medical talent and drive breakthroughs at the frontiers of medicine. Through close collaboration between the two campuses, we aim to align with the national "Healthy China" agenda and the Greater Bay Area's innovation development strategy, jointly building a globally influential hub for medical innovation and talent development."
This strategic cross-boundary appointment reflects the forward-looking strategic vision and holistic perspective of both Hong Kong and Shenzhen. CU Medicine has a strong foundation in medical education, clinical services, frontier research and healthcare innovation, while Shenzhen offers a vibrant innovation ecosystem and significant opportunities for clinical research and technology translation.
By serving concurrently as dean of both medical schools, Professor Chiu will help align and complement the development strategies of the two institutions, strengthen communication and coordination, capitalise on the unique advantages of Hong Kong and Shenzhen, support the advancement of the School of Medicine at CUHK-Shenzhen toward greater internationalisation and academic excellence, and expand CUHK's footprint in healthcare innovation.
This initiative not only serves as a key measure to align with the national GBA strategy and support the implementation of the "Healthy China" agenda, but also represents a visionary, epoch-making alignment with the global frontier of medicine. It will inject powerful momentum into jointly building an internationally influential medical technology innovation ecosystem across both cities, while advancing the development of human health and healthcare worldwide.
CUHK website: https://www.cuhk.edu.hk/
CUHK-Shenzhen website: https://www.cuhk.edu.cn/
Video of CUHK Integrating into the Greater Bay Area: https://www.youtube.com/watch?v=uTZtdXKJu-Q
Hashtag: #CUHK #CUHKShenzhen #CUMedicine #PhilipChiu #OneBrandTwoCampuses #GreaterBayArea #MedicalInnovation #HealthcareInnovation #MedicalEducation #TranslationalResearch #GlobalTalent #HealthyChina
https://www.linkedin.com/school/13045
https://x.com/cuhkofficial
https://www.facebook.com/CUHKofficial
https://www.instagram.com/thechineseuniversityofhongkong/
https://www.youtube.com/user/CUHKchannel
The issuer is solely responsible for the content of this announcement.
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
